Compare
Palatin Technologies Inc vs Tonix Pharmaceuticals Holding Corp. vs Evommune, Inc. vs Pyxis Oncology, Inc.
| Latest fiscal year | Palatin Technologies Inc PTN | Tonix Pharmaceuticals Holding Corp. TNXP | Evommune, Inc. EVMN | Pyxis Oncology, Inc. PYXS |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $13.19M | $13.11M | $13.00M | $13.86M |
| Revenue growth (YoY) | n/a | +29.8% | +85.7% | -14.2% |
| Gross margin | n/a | 49.3% (computed) | n/a | 82.8% (computed) |
| Operating margin | -65.7% | -959.1% | -623.6% | -609.2% |
| Net margin | -63.5% | -946.2% | -529.8% | -574.5% |
| Net income | -$8.38M | -$124.02M | -$68.87M | -$79.62M |
| EPS (Diluted) | -$2.96 | -$14.57 | -$11.22 | -$1.28 |
| Operating cash flow | -$13.53M | -$99.84M | -$76.44M | -$63.50M |
| Free cash flow | -$13.58M | -$103.21M | -$76.68M | -$63.51M |
| Cash & equivalents | $7.49M | $207.64M | $44.06M | $15.42M |
| Total assets | $8.52M | $277.17M | $224.95M | $91.52M |
| Total liabilities | $1.84M | $32.02M | $19.38M | $38.11M |
| Shareholders' equity | $6.69M | $245.15M | $205.57M | $53.41M |
| Return on year-end equity | -125.3% | -50.6% | -33.5% | -149.1% |
| Shares outstanding | 1.78M | 12.79M | 31.52M | 62.69M |
Revenue, most recent five fiscal years
| Fiscal year | Palatin Technologies Inc | Tonix Pharmaceuticals Holding Corp. | Evommune, Inc. | Pyxis Oncology, Inc. |
|---|---|---|---|---|
| Latest | $13.19M Ended 2026-06-30 | $13.11M Ended 2025-12-31 | $13.00M Ended 2025-12-31 | $13.86M Ended 2025-12-31 |
| 1 year earlier | n/a | $10.09M Ended 2024-12-31 | $7.00M Ended 2024-12-31 | $16.15M Ended 2024-12-31 |
| 2 years earlier | n/a | $7.77M Ended 2023-12-31 | n/a | n/a |
| 3 years earlier | n/a | n/a | n/a | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |